Triplet Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company leveraging human genetics to develop treatments for repeat expansion disorders at their source, raised $59m in financing.
This includes a $49m Series A financing led by MPM Capital and Pfizer Ventures U.S. LLC, the venture capital arm of Pfizer Inc. (NYSE: PFE). Atlas Venture, which co-founded and seeded Triplet with a $10m investment, also participated in the Series A alongside Invus, Partners Innovation Fund and Alexandria Venture Investments.
The company will use the funds to progress its first development candidates into IND-enabling studies, as well as to advance natural history studies to inform its clinical development plan and contribute to the scientific understanding of repeat expansion disorders.
Founded in 2018 by Nessan Bermingham, Ph.D., a serial biotech entrepreneur and venture partner at Atlas Venture, along with Atlas Venture and Andrew Fraley, Ph.D., Triplet is developing antisense oligonucleotide (ASO) and small interfering RNA (siRNA) development candidates to precisely knock down key components of the DDR pathway that drive repeat expansion. By precisely reducing activity of select DDR targets, the company’s approach is designed to halt onset and progression across a wide range of repeat expansion disorders.
The company’s senior management includes:
- Nessan Bermingham, Ph.D., co-founder, president and chief executive officer,
- Irina Antonijevic, M.D., Ph.D., senior vice president of development,
- Brian Bettencourt, Ph.D., senior vice president of computational biology & statistics,
- David Morrissey, Ph.D., senior vice president of technology,
- Eric Sullivan, CPA, chief financial officer, and Jeffrey
- M. Cerio, Pharm.D., J.D., senior vice president & general counsel.